Peripheral blood mononuclear cells-expressed miRNA profiles derived from children with metabolic-associated fatty liver disease and insulin resistance.
MiRNA
children
fatty liver
insulin resistance
metabolic diseases
obesity
Journal
Pediatric obesity
ISSN: 2047-6310
Titre abrégé: Pediatr Obes
Pays: England
ID NLM: 101572033
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
21
07
2022
received:
15
03
2022
accepted:
25
07
2022
pubmed:
3
9
2022
medline:
15
11
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
miRNA have been proposed as potential biomarkers of metabolic diseases. To identify potential miRNA biomarkers of early metabolic-associated fatty liver disease (MAFLD) and/or insulin resistance (IR) in preadolescent children. A total of 70 preadolescents, aged 8.5-12 years old participated in the study. Hepatic fat was assessed by magnetic resonance imaging. Fasting blood biochemical parameters were measured and HOMA-IR calculated. Peripheral blood mononuclear cells (PBMC)-derived miRNA profiles associated with MAFLD (≥5.5% hepatic fat) and IR (HOMA-IR ≥2.5) were identified using untargeted high-throughput miRNAs sequencing (RNA-seq). A total of 2123 PBMC-derived miRNAs were identified in children with (21.4%) or without MAFLD. Among them, hsa-miR-143-3p, hsa-miR-142-5p and hsa-miR-660-5p were up-regulated, and p-hsa-miR-247, hsa-let-7a-5p and hsa-miR-6823-3p down-regulated. Importantly, children with MAFLD had consistently higher miR-660-5p expression levels than their peers without it (p < 0.01), regardless of weight status. A total of 2124 PBMC-derived miRNA were identified in children with IR (28.6%) versus children without IR, where thirteen of them were dysregulated (p < 0.05) in children with IR. In addition, children with IR showed higher levels of miR-374a-5p and miR-190a-5p (p < 0.01) and lower levels of miR-4284 and miR-4791 (p < 005), than their peers without IR in both the whole sample and in those with overweight or obesity. Our study results suggest circulating miR-660-5p as a potential biomarker of the presence of MAFLD in preadolescent children while circulating miR-320a, miR-142-3p, miR-190a-5p, miR-374a-5p and let-7 family miRNAs could serve as potential biomarkers of IR in children.
Sections du résumé
BACKGROUND
miRNA have been proposed as potential biomarkers of metabolic diseases.
OBJECTIVES
To identify potential miRNA biomarkers of early metabolic-associated fatty liver disease (MAFLD) and/or insulin resistance (IR) in preadolescent children.
METHODS
A total of 70 preadolescents, aged 8.5-12 years old participated in the study. Hepatic fat was assessed by magnetic resonance imaging. Fasting blood biochemical parameters were measured and HOMA-IR calculated. Peripheral blood mononuclear cells (PBMC)-derived miRNA profiles associated with MAFLD (≥5.5% hepatic fat) and IR (HOMA-IR ≥2.5) were identified using untargeted high-throughput miRNAs sequencing (RNA-seq).
RESULTS
A total of 2123 PBMC-derived miRNAs were identified in children with (21.4%) or without MAFLD. Among them, hsa-miR-143-3p, hsa-miR-142-5p and hsa-miR-660-5p were up-regulated, and p-hsa-miR-247, hsa-let-7a-5p and hsa-miR-6823-3p down-regulated. Importantly, children with MAFLD had consistently higher miR-660-5p expression levels than their peers without it (p < 0.01), regardless of weight status. A total of 2124 PBMC-derived miRNA were identified in children with IR (28.6%) versus children without IR, where thirteen of them were dysregulated (p < 0.05) in children with IR. In addition, children with IR showed higher levels of miR-374a-5p and miR-190a-5p (p < 0.01) and lower levels of miR-4284 and miR-4791 (p < 005), than their peers without IR in both the whole sample and in those with overweight or obesity.
CONCLUSIONS
Our study results suggest circulating miR-660-5p as a potential biomarker of the presence of MAFLD in preadolescent children while circulating miR-320a, miR-142-3p, miR-190a-5p, miR-374a-5p and let-7 family miRNAs could serve as potential biomarkers of IR in children.
Identifiants
pubmed: 36054529
doi: 10.1111/ijpo.12966
pmc: PMC9787576
doi:
Substances chimiques
MicroRNAs
0
Biomarkers
0
MIRN660 microRNA, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12966Informations de copyright
© 2022 The Authors. Pediatric Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
Références
Int J Obes (Lond). 2021 Aug;45(8):1763-1772
pubmed: 33986456
PLoS One. 2016 Apr 14;11(4):e0153497
pubmed: 27077736
Metabolism. 2015 Sep;64(9):1051-9
pubmed: 26031505
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):864-873
pubmed: 34364544
J Clin Med. 2015 Dec 04;4(12):1977-88
pubmed: 26690233
Pediatr Obes. 2022 Aug;17(8):e12910
pubmed: 35289984
Front Genet. 2019 Jun 04;10:531
pubmed: 31275351
IUBMB Life. 2020 Mar;72(3):361-372
pubmed: 31889412
Nutrients. 2014 Aug 21;6(8):3303-25
pubmed: 25195642
Exp Ther Med. 2021 Sep;22(3):943
pubmed: 34306207
Diabetologia. 2015 May;58(5):900-11
pubmed: 25677225
Pediatr Obes. 2022 Dec;17(12):e12966
pubmed: 36054529
J Pediatr. 2019 Apr;207:64-70
pubmed: 30559024
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Int J Mol Sci. 2017 Feb 28;18(3):
pubmed: 28264477
Lancet Diabetes Endocrinol. 2019 Apr;7(4):313-324
pubmed: 30174213
PLoS One. 2015 May 28;10(5):e0128372
pubmed: 26020947
Inflamm Bowel Dis. 2015 May;21(5):996-1005
pubmed: 25738378
Nutrients. 2020 Oct 16;12(10):
pubmed: 33081177
Trials. 2017 Aug 10;18(1):372
pubmed: 28793919
Genome Biol. 2014;15(12):550
pubmed: 25516281
Mol Ther Nucleic Acids. 2021 Aug 26;26:444-457
pubmed: 34631276
Diabetes. 2001 Aug;50(8):1844-50
pubmed: 11473047
J Diabetes. 2020 Sep;12(9):633-644
pubmed: 29341487
Hepatology. 2004 Dec;40(6):1387-95
pubmed: 15565570
Pediatr Obes. 2017 Jun;12(3):229-238
pubmed: 27059430
Pediatr Obes. 2018 Mar;13(3):175-182
pubmed: 29271122
World J Gastroenterol. 2016 Sep 28;22(36):8078-93
pubmed: 27688650
Metabolism. 2016 Aug;65(8):1038-48
pubmed: 26823198
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
J Hepatol. 2018 Dec;69(6):1335-1348
pubmed: 30142428
JAMA Pediatr. 2016 Oct 03;170(10):e161971
pubmed: 27478956
Diabetes Care. 2014;37(5):1375-83
pubmed: 24478399
Metabolism. 2016 Aug;65(8):1017-25
pubmed: 26997539
Aging (Albany NY). 2021 Jun 15;13(11):15690
pubmed: 34129523
Liver Int. 2014 Aug;34(7):e302-7
pubmed: 24313922
Clin Obes. 2017 Aug;7(4):216-221
pubmed: 28397375
Contemp Clin Trials. 2015 Nov;45(Pt B):346-355
pubmed: 26408054
World J Gastroenterol. 2017 Sep 28;23(36):6571-6592
pubmed: 29085206
PLoS One. 2015 Oct 29;10(10):e0140908
pubmed: 26512983
Bioorg Med Chem. 2022 Mar 1;57:116593
pubmed: 35093804
Clin Nutr. 2019 Oct;38(5):2231-2238
pubmed: 30309709
Pediatr Obes. 2022 Jun;17(6):e12880
pubmed: 34918493
BMC Endocr Disord. 2020 Sep 29;20(1):145
pubmed: 32988370
Cells. 2019 Nov 28;8(12):
pubmed: 31795194
Hum Mol Genet. 2011 Oct 15;20(20):4025-40
pubmed: 21807764
Obes Rev. 2016 Dec;17(12):1258-1275
pubmed: 27452904
Pediatr Obes. 2012 Aug;7(4):284-94
pubmed: 22715120
Clin Chem. 2013 May;59(5):781-92
pubmed: 23396142
Cancer Manag Res. 2021 Jul 28;13:5865-5872
pubmed: 34349559
Mol Aspects Med. 2017 Apr;54:78-88
pubmed: 27889327